The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., has sided with EOFlow in its patent spat with Insulet (Nasdaq:PODD). In its decision, the court overturned a verdict from 2024 that ordered EOFlow to pay nearly $60 million to Insulet. A jury found that EOFlow and several other defendants misappropriated Insulet’s trade secrets […]
Insulet
Insulet initiates another Omnipod 5 recall affecting 7 million devices including some Dash, Eros systems
Insulet (Nasdaq:PODD) today announced a voluntary medical device correction for specific lots of its Omnipod 5, Dash and Eros pods. The company identified a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery with the affected current-generation Omnipod 5, previous-generation Omnipod Dash or the prior Omnipod Insulin Management System (Eros). Insulet said […]
Insulet sales grow 34% in Street-beating Q1 as company ups growth guidance
Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on Wall Street. Shares of PODD ticked up 5% to $175.79 before the market opened today. However, at midday, shares were down 8.2% at $153.78 apiece, potentially in response to scrutiny over U.S. trends and new patient starts. The […]
Insulet initiates study of fully closed-loop insulin delivery in type 2 diabetes
Insulet (Nasdaq:PODD) announced today that it enrolled the first participant in a study of its fully closed-loop automated insulin delivery system for type 2 diabetes. Acton, Massachusetts-based Insulet aims to bring a fully closed-loop (FCL) system to the type 2 diabetes population to further improve glycemic outcomes with less burden for users across diverse settings. […]
FDA says Insulet Omnipod 5 recall is serious after 476 device reports, issue is potentially undetectable by user
The FDA says last month’s recall of Insulet (Nasdaq:PODD) Omnipod 5 insulin pump pods has been identified as its most serious type. According to the FDA, such a recall may cause serious injury or death with continued use. Insulet announced on March 12 that it initiated a voluntary medical device correction for specific lots of […]
How Insulet taps into pop culture to spread the word on Omnipod through ‘Scrubs,’ Marvel
For those familiar with diabetes technology, the Omnipod platform from Insulet (Nasdaq:PODD) is one most will know about. Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — is one of the leading pumps on the market. But, for those less familiar with the technology, Insulet has found new ways to […]
Insulet names J&J Medtech veteran as new SVP, chief quality, regulatory & compliance officer
Insulet (Nasdaq:PODD) announced on social media today that it appointed a new SVP, chief quality, regulatory and compliance officer. The company picked medical device industry veteran Chuck Medovich to take on the role. Medovich brings more than 30 years of experience across quality, regulatory, manufacturing and R&D functions. His track record includes more than two […]
Insulet picks longtime Stryker leader as new chief commercial officer
Insulet (Nasdaq:PODD) announced today that it appointed Mike Panos as EVP, chief commercial officer (CCO), effective immediately. In this role, Panos takes responsibility for the Acton, Massachusetts-based automated insulin delivery system developer’s global commercial organization. He reports to President and CEO Ashley McEvoy and serves on the executive leadership team. Panos brings 30 years of […]
The biggest diabetes tech news out of ATTD 2026
Diabetes technology innovators gathered in Barcelona last week for the 19th annual Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026). At ATTD 2026, a range of companies shared the latest updates, including product launches, new clinical data, enhancements to existing offerings and more. Topics included automated insulin delivery, continuous glucose monitors (CGMs), and breakthroughs […]
Insulet issues warning on certain Omnipod 5 pumps due to manufacturing issue
Insulet (Nasdaq:PODD) today initiated a voluntary medical device correction for specific lots of Omnipod 5 insulin pump pods. Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — is a patch-based pump system designed to proactively correct for glucose highs every five minutes and protect against lows with insulin dosing. Acton, […]
